Skip to main content
. 2018 Jul 17;28(10):786–801. doi: 10.1093/glycob/cwy057

Fig. 6.

Fig. 6.

Keratanase treatment of human trachea tissue sections diminishes Siglec-8-Fc binding. Cross sections of human trachea were incubated with Siglec-8-Fc precomplexed with AP-conjugated anti-human-Fc (A–C) or Siglec-8-Fc followed with the same secondary antibody (D–F) as described in the text. Lectin binding was detected using Vector Red stain and sections counterstained using hematoxylin QS. (A–C) Low-power images of serial sections of human trachea preincubated for 24 h at 37°C with buffer alone (A), 0.2 mU/mL keratanase I (B), or 5 mU/mL keratanase II (C) prior to Siglec-8-Fc overlay. Arrows, submucosal glands; arrowheads, cartilage. (D–F) Higher power images of human tracheal submucosal glands from sections preincubated for 25 h at 37°C with buffer alone (D), 21 mU/mL keratanase I (E), or 10 mU/mL keratanase II (F).